Use Of Migalostat In Reducing The Risk Of Cerebrovascular Event In Patients With Fabry Disease
Patent No. EP3914247 (titled "Use Of Migalostat In Reducing The Risk Of Cerebrovascular Event In Patients With Fabry Disease") was filed by Amicus Therapeutics on Jan 22, 2020. The application was issued on Nov 13, 2024.
Patent Summary
Treatment of Fabry disease using migalastat, a pharmacological chaperone that stabilizes mutant forms of the lysosomal enzyme alpha-galactosidase A (α-Gal A). Migalastat selectively binds to α-Gal A and facilitates its proper trafficking to lysosomes, reducing the accumulation of globotriaosylceramide (GL-3) and related glycosphingolipids. The treatment is effective in both ERT-naive and ERT-experienced patients, and has been shown to reduce the risk of cerebrovascular events.
Patent Family
Patent Oppositions (3)
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP3914247
- Application Number
- EP20708283A
- Filing Date
- Jan 22, 2020
- Status
- Granted And Under Opposition
- Oct 11, 2024
- Publication Date
- Nov 13, 2024
- External Links
- Slate, Register , Google Patents